It is now appreciated that cerebral 3-hydroxykynurenine and quinolinic acid concentrations can be manipulated, selectively without altering KYNA concentrations, by inhibition of KMO[49], an approach which shows neuroprotective effects in animal models of cerebral ischemia[19]. This evidence concerns the gene KMO and brain ischemia.